• Aimmune Therapeutics

  Participated · Series A · Nov 2013

  Aimmune Therapeutics is developing a peanut allergy drug. An NDA filing for the drug looms. Rivalry around the program has intensified. Nestlé Health Science increased its investment by $98 million, bringing its stake to $276 million. The article frames the move as Nestlé upping its bet as regulatory and competitive pressures mount. No operating metrics were provided in the article. Aimmune is a Brisbane, California–based biotech focused on food allergy research and development. The company is publicly traded under the ticker $AIMT. Nestlé Health Science invested $145 million to support Aimmune’s food allergy R&D work. The article describes Nestlé as taking the head seat at the deal table, indicating it led the transaction. The piece refers to Aimmune as an emerging biotech company. No additional operating metrics, product details, or other investors were disclosed in the article. Allergen Research Corporation develops characterized oral desensitization immunotherapy (CODIT™) products for food allergies, combining standardized, pharmaceutical‑grade food allergens with controlled up‑dosing protocols. Its lead product, AR 101, is a standardized peanut protein formulation that completed a successful multicenter, randomized, double‑blind, placebo‑controlled Phase 2 trial and has received FDA Fast Track designation. The company plans to advance AR 101 into a planned Phase 3 clinical trial and will use recent financing to fund that pivotal study. ARC also intends to begin clinical development of CODIT products for egg and milk allergies in the coming year. Founded in 2011 and based in San Mateo, California, ARC aims to commercialize standardized OIT approaches to increase patients' allergic thresholds and reduce the risk from accidental exposure. The company previously completed a $17 million Series A in November 2013. Allergen Research Corporation (ARC) is developing desensitization treatment protocols and clinical products for food allergies, building on more than a decade of oral immunotherapy research by academic and nonprofit collaborators. Its lead product is a pharmaceutical‑grade formulated peanut protein now in Phase 2b development for oral immunotherapy (OIT) using characterized peanut allergen (CPNA). ARC plans to begin a Phase 2b trial in the fourth quarter of 2013 to evaluate peanut OIT with CPNA, and the recent financing will support that trial and related development projects. The company’s broader mission is to develop OIT products for the foods that account for the majority of reactions: peanut, milk, eggs, wheat, soy, shellfish, fish and tree nuts. ARC was founded in 2011 and aims to establish standardized allergen desensitization treatment protocols and supply treatment products for clinical use. The company recently completed a Series A financing to fund its near-term clinical program.

No current team members are available.